Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of a medicine called BI 764198 in adults and adolescents with a kidney disease known as focal segmental glomerulosclerosis FSGS. This Phase 3 study aims to understand whether BI 764198 can help people with primary FSGS or genetic FSGS related to TRPC6 gene mutations. The trial is randomized, double-blind, and placebo-controlled, comparing BI 764198 tablets to placebo tablets. Participants take one tablet daily for up to two years alongside their usual FSGS treatments. They are randomly assigned to either the BI 764198 group or the placebo group, with equal chance to be in either. The study monitors participants over 104 weeks, collecting urine samples regularly to assess kidney function and compare results between groups. During the study, participants visit the study site about every three months for health assessments and safety monitoring. Researchers measure changes in urine protein-creatinine ratio and kidney filtration rate to evaluate treatment response. Additional questionnaires assess disease impact. The total participation time is up to two years, allowing long-term evaluation of the treatments effects and safety.
Actively Recruiting
Researchers are evaluating whether metformin, a medication commonly used for diabetes, can be repurposed to slow kidney function decline in adults diagnosed with early-stage Autosomal Dominant Polycystic Kidney Disease ADPKD. ADPKD causes cyst growth in kidneys leading to pain, high blood pressure, chronic kidney disease, and reduced quality of life. This global Phase III randomized controlled trial aims to find effective, affordable treatments to reduce illness impact and improve life quality for ADPKD patients. Participants are randomly assigned to receive either extended-release metformin Metformin XR or a placebo, alongside standard care, for 104 weeks. The metformin dose ranges from 500 to 2000 mg daily based on individual tolerance and kidney function. The study includes a control group receiving identical placebo tablets for comparison. This design allows assessment of metformins effect on slowing disease progression. During the study, participants undergo regular monitoring including kidney function tests, assessment of kidney disease progression, quality of life questionnaires, and tracking of side effects and healthcare use over 24 months. The primary outcome is the change in estimated glomerular filtration rate eGFR. Secondary outcomes include kidney failure, mortality, medication dosing changes, and symptoms related to ADPKD. Safety and effectiveness are carefully followed throughout the trial period, which may last until 2030.
Actively Recruiting
Researchers are evaluating new treatments for acute hypoxemic respiratory failure AHRF, a serious lung condition affecting millions worldwide and often leading to death or long-term health issues. This adaptive platform trial tests different interventions across varying severity levels, including non-intubated patients, those on mechanical ventilation, and patients needing extracorporeal life support. The study uses an advanced Bayesian design to efficiently assess multiple therapies and strategies, focusing on improving outcomes for critically ill patients. The trial includes several domains studying various therapies such as ultra-protective ventilation with extracorporeal CO2 removal, different mechanical ventilation strategies, corticosteroid use, and new drug treatments like fludrocortisone and nebulized furosemide. Interventions may involve adjusting ventilator settings, sedation, rehabilitation, or medication dosing over periods ranging from days to weeks. Some domains are observational and collect detailed biomarker and clinical data. The platform allows adding or dropping interventions based on ongoing results, optimizing research efficiency. Participants will undergo regular assessments including physiological and biological measurements, respiratory function tests, and monitoring of clinical outcomes like mortality, ventilator-free days, and organ function scores. Safety and adherence to protocols are closely tracked throughout. The study duration varies by intervention, with some domains enrolling patients over two years and monitoring outcomes up to six months. Participants may experience multiple visits for treatment adjustments, data collection, and follow-up evaluations.
Actively Recruiting
Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.
Actively Recruiting
This research aims to find out whether an early three-day oral steroid treatment called dexamethasone can improve both physical and mental recovery in children with Sydenhams chorea. Sydenhams chorea is a movement disorder caused by brain inflammation after an abnormal immune response to certain bacterial infections, affecting childrens movements, mood, and concentration. The condition commonly affects children with acute rheumatic fever, and recovery can take months. The study is a phase 3, randomized, double-blinded, placebo-controlled trial involving children in New Zealand and Australia. Participants will be randomly assigned to receive either oral dexamethasone or a placebo for three days. The dexamethasone dose is 20 mg per square meter of body surface per day, divided into three doses, with a maximum of 24 mg per day. The placebo group will take matching capsules on the same schedule. This short course treatment is being tested to see if it reduces the severity of Sydenhams chorea and its psychiatric symptoms. Children in the study will be monitored through scheduled visits on days three, seven, one month, three months, and twelve months. Researchers will assess chorea severity, relapse rates, psychiatric symptoms, hospital stay length, and treatment failure. Safety will be checked for any side effects possibly related to dexamethasone. The trial plans to recruit 80 participants, and overall involvement may last up to 12 months to track recovery and treatment effects comprehensively.